189299
ATR/CDK Inhibitor, NU6027
The ATR/CDK Inhibitor, NU6027, also referenced under CAS 220036-08-8, controls the biological activity of ATR/CDK. This small molecule/inhibitor is primarily used for Cancer applications.
登录查看公司和协议定价
所有图片(2)
别名:
ATR/CDK Inhibitor, NU6027, ATR Inhibitor, NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, CDK2 Inhibitor, NU6027
经验公式（希尔记法）:
C11H17N5O2
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
red-purple
溶解性
DMSO: 10 mg/mL, clear, blue
运输
ambient
储存温度
−20°C
InChI
1S/C11H17N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h7H,1-6H2,(H4,12,13,14,15)
InChI key
DGWXOLHKVGDQLN-UHFFFAOYSA-N
一般描述
A cell-permeable, pyrimidine derivative that acts as an ATP-competitive CDK Inhibitor (Ki = 2.5 µM for CDK1, and Ki = 1.3 µM for CDK2), and demonstrates cytostatic properties among a panel of 57 cancer cell lines. Also inhibits ATR kinase (IC50 = 6.7 µM in MCF7 cells), but does not interfere with irradiation-induced autophosphorylation of DNA-PK or ATM. Potentiates a range of DNA-damaging cytotoxic drugs such as hydroxyurea (1.8-fold) and cisplatin (1.4-fold) at 10 µM, but not the anti-mitotic paclitaxel. Attenuates G2/M arrest following DNA damage and inhibits RAD51 focus formation. Shown to be synthetically lethal when DNA single-strand break repair is impaired in PARP-inhibited cells.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
其他说明
Peasland, A., et al. 2011., Br J Cancer. 105, 372.
Arris, C.E, et al. 2000., J Med Chem.43, 2797.
Arris, C.E, et al. 2000., J Med Chem.43, 2797.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门